Mineralys presents lorundrostat data in kidney disease patients

Mineralys Therapeutics reported encouraging Phase 3 Launch-HTN data for lorundrostat, including placebo-adjusted systolic blood pressure reductions of 9.6 mmHg in CKD patients and 12.2 mmHg in non-CKD patients at week 12. In CKD participants with baseline albuminuria, the drug cut urinary albumin-to-creatinine ratio by 52.2% placebo-adjusted, while confirmed hyperkalemia remained low at 2.4% in CKD and 0% in non-CKD patients. The FDA review remains pending with a target decision date of December 22, 2026; the company also cited a Q1 2026 EPS loss of $0.47 versus a $0.81 expected loss and analyst targets of $30 to $56.

Analysis

MLYS is increasingly a “data derisking” story, not just a binary FDA event. The CKD subgroup matters because it shows the drug may be most commercially valuable in exactly the population where standard BP regimens are hardest to optimize and where a kidney-protective signal can expand duration of therapy and physician persistence; that combination can justify a higher peak-sales multiple than a pure hypertension add-on. The bigger second-order effect is competitive: if aldosterone synthase inhibition becomes the preferred fourth-line mechanism, it pressures MRAs, some SGLT2-combo narratives, and any late-stage antihypertensive programs that lack a renal biomarker hook.

The market is likely underpricing the asymmetry between approval and launch execution. A clean label and a manageable potassium profile would support rapid uptake by nephrology and hypertension specialists, but reimbursement could be the real gating factor because payers will push to confine use to resistant-HTN and CKD subsets until renal outcome data emerge. That makes near-term stock performance more sensitive to FDA language and launch guidance than to the trial itself; if the label narrows or monitoring requirements are burdensome, the multiple can compress quickly despite positive efficacy.

The contrarian risk is that investors are extrapolating a broad hypertension franchise from a dataset that still needs commercial proof. The stock has already rerated sharply, so even modest execution misses, slower prescription velocity, or a “not first-line” label could trigger de-risking over the next 3-6 months. The longer-dated upside remains intact if management converts the CKD albuminuria signal into a payer-friendly nephroprotection story, but that is a 12-24 month thesis, not a next-quarter trade.

Key Decisions for Investors

• Maintain a tactical long in MLYS into the FDA decision window, but size it as an event-driven position only; target upside is another re-rating if label language is broad, while downside is sharp if monitoring or indicated-use constraints narrow the commercial opportunity.
• Buy call spreads in MLYS on pullbacks over the next 2-6 weeks to express upside into regulatory catalysts while capping exposure to valuation compression; best risk/reward is a defined-risk structure rather than outright equity after the recent run.
• Pair trade: long MLYS / short a basket of slower-growing hypertension or renal-adjacent biotech comps if you want to isolate regulatory derisking versus general biotech beta; thesis is MLYS has a clearer near-term catalyst path than the average mid-cap biotech.
• If FDA language suggests heavy potassium monitoring or a restricted CKD-first label, fade the move with a short-term short or put spread; that setup should work over days to weeks as launch expectations reset.
• For longer-only accounts, wait for post-label execution confirmation before adding; the cleaner entry is after the first prescription/early access data, when launch quality can be judged over 1-2 quarters rather than on headline trial enthusiasm.